PASSAGE BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
PASSAGE BIO, INC. (PASG) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $73.84 per share for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-09-03
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $2.02, a 83.71% decline from fiscal 2023.
- PASSAGE BIO, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $12.40.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|
| 2026-06-30 | $73.84 S-4/A · filed 2026-09-03 | ||
| 2025-12-31 | $175.24 S-4/A · filed 2026-09-03 | ||
| 2025-09-30 | $175.24 10-Q · filed 2025-11-10 | ||
| 2024-12-31 | $2.02 10-K · filed 2025-03-04 | ||
| 2023-12-31 | $12.40 10-K · filed 2024-03-04 | ||
| 2023-09-30 | $12.50 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |